Ionizing radiation affects epidermal growth factor receptor signalling and metalloproteinase secretion in glioma cells

Cancer Genomics and Proteomics

Volumn 8, Issue 1, 2011, Pages 33-38

  Martinou, Maria ^a   Giannopoulou, Efstathia ^a   Malatara, Georgia ^a   Argyriou, Andreas A ^a   Kalofonos, Haralabos P ^a   Kardamakis, Dimitrios ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

EGFR; Gliomas; Ionizing radiation; MMPs

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; LIPOCORTIN 5;

APOPTOSIS; ARTICLE; BINDING ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IONIZING RADIATION; IRRADIATION; PROTEIN PHOSPHORYLATION; RADIATION DOSE; ROOM TEMPERATURE; SECRETION; SIGNAL TRANSDUCTION; ZYMOGRAPHY;

EID: 79951977311     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Barker FG 2nd, Prados MD, Chang SM, Gutin PH, Lamborn KR, Larson DA, Malec MK, McDermott MW, Sneed PK and Wilson CB: Radiation response and survival time in patients with glioblastoma multiforme. J Neurosurg 84: 442-448, 1996. (Pubitemid 26062869)
2. Argyriou AA, Antonacopoulou A, Iconomou G and Kalofonos HP: Treatment options for malignant gliomas, emphasizing towards new molecularly targeted therapies. Crit Rev Oncol Hematol 69: 199-210, 2009.
3. Taghian A, DuBois W, Budach W, Baumann M, Freeman J and Suit H: In vivo radiation sensitivity of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 32: 99-104, 1995.
4. Onda K, Davis RL, Shibuya M, Wilson CB and Hoshino T: Correlation between the bromodeoxyuridine labelling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas. Cancer 74: 1921-1926, 1994.
5. Davis FG, Freels S, Grutsch J, Barlas S and Brem S: Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg 88: 1-10, 1998.
6. Jiang H, Xu Y, Li W, Ma K, Cai L and Wang G: Low-dose radiation does not induce proliferation in tumor cells in vitro and in vivo. Radiat Res 170: 477-487, 2008.
7. Williams JR, Zhang Y, Zhou H, Gridley DS, Koch CJ, Slater JM and Little JB: Overview of radiosensitivity of human tumor cells to low-dose-rate irradiation. Int J Radiat Oncol Biol Phys 72: 909-917, 2008.
8. Beauchesne PD, Bertrand S, Branche R, Linke SP, Revel R, Dore JF and Pedeux RM: Human malignant glioma cell lines are sensitive to low radiation doses. Int J Cancer 105: 33-40, 2003. (Pubitemid 36418482)
9. Joiner MC, Lambin P, Malaise EP, Robson T, Arrand JE, Skov KA and Marples B: Hypersensitivity to very-low single radiation doses: its relationship to the adaptive response and induced radioresistance. Mutat Res 358: 171-183, 1996. (Pubitemid 26384287)
10. Brada M: Radiotherapy in malignant glioma. Ann Oncol 17(Suppl 10): x183-x185, 2006.
11. Basset P, Okada A, Chenard MP, Kannan R, Stoll I, Anglard P, Bellocq JP and Rio MC: Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutical implications. Matrix Biol 15: 535-541, 1997. (Pubitemid 27190028)
12. Rao JS: Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 3: 489-501, 2003.
13. Rooprai HK, Rucklidge GJ, Panou C and Pilkington GJ: The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumour cells. Br J Cancer 82: 52-55, 2000. (Pubitemid 30008958)
14. Uhm JH, Dooley NP, Villemure JG and Yong VW: Glioma invasion in vitro: regulation by matrix metalloprotease- 2 and protein kinase C. Clin Exp Metastasis 14: 421-433, 1996.
15. Nakano A, Tani E, Miyazaki K, Yamamoto Y and Furuyama J: Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. J Neurosurg 83: 298-307, 1995.
16. Argyriou AA, Giannopoulou E and Kalofonos HP: Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas. Oncology 77: 1-11, 2009.
17. Wild-Bode C, Weller M and Wick W: Molecular determinants of glioma cell migration and invasion. J Neurosurg 94: 978-984, 2001. (Pubitemid 32799599)
18. Lampert K, Machein U, Machein MR, Conca W, Peter HH and Volk B: Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors. Am J Pathol 153: 429-437, 1998. (Pubitemid 28373654)
19. Park CM, Park MJ, Kwak HJ, Lee HC, Kim MS, Lee SH, Park IC, Rhee CH and Hong SI: Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/Epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. Cancer Res 66: 8511-8519, 2006. (Pubitemid 44449164)
20. Chakravarti A, Dicker A and Mehta M: The contribution of epidermal growth factor receptor (EGFR) signalling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. Int J Radiat Oncol Bio Phys 58: 927-931, 2004.
21. Gunther W, Skaftnesmo KO, Arnold H and Terzis AJ: Molecular approaches to brain tumour invasion. Acta Neurochir (Wien) 145: 1029-1036, 2003. (Pubitemid 38091017)
22. Mischet PS and Cloughesy TF: Targeted molecular therapy of GBM. Brain Pathol 13: 52-61, 2003.
23. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L and Parsons R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947, 1997.
24. Lu Y, Lin YZ, LaPushin R, Cuevas B, Fang X, Yu SX, Davies MA, Khan H, Furui T and Mills GB: The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene 18: 7034-7045, 1999.
25. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R and Yamada KM: Inhibition of cell migration, spreading, and focal adhesion by tumor suppressor PTEN. Science (Wash) 280: 1614-1617, 1998. (Pubitemid 28277707)
26. Giannopoulou E, Katsoris P, Hatziapostolou M, Kardamakis D, Kotsaki E, Polytarchou C, Parthymou A, Papaioannou S and Papadimitriou E: X-rays modulate extracellular matrix in vivo. Int J Cancer 94: 690-698, 2001.
27. Parthymou A, Kardamakis D, Pavlopoulos I and Papadimitriou E: Irradiated C6 glioma cells induce angiogenesis in vivo and activate endothelial cells in vitro. Int J Cancer 110: 807-814, 2004. (Pubitemid 38758505)
28. Giannopoulou E, Antonacopoulou A, Floratou K, Papavassiliou AG and Kalofonos HP: Dual targeting of EGFR and HER-2 in colon cancer cell lines. Cancer Chemother Pharmacol 63: 973-981, 2009.
29. Giannopoulou E and Papadimitriou E: Amifostine has antiangiogenic properties in vitro by changing the redox status of human endothelial cells. Free Radic Res 37: 1191-1199, 2003.
30. Feinendegen LE, Pollycove M and Sondhaus CA: Responses to low doses of ionizing radiation in biological systems. Nonlinearity Biol Toxicol Med 2: 143-171, 2004.
31. Short SC, Mitchell SA, Boulton P, Woodcock M and Joiner MC: The response of human glioma cell lines to low-dose radiation exposure, Int J Radiat Biol 75: 1341-1348, 1999.
32. Tubiana M: Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review. Radiother Oncol 91: 4-15, 2009.
33. Combs SE, Schulz-Ertner D, Roth W, Herold-Mende C, Debus J and Weber KJ: In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab. Int J Radiat Oncol Biol Phys 68: 873-882, 2007.
34. Overall CM and Kleifeld O: Validating matrix metalloproteinases as drugs targets and anti-targets for cancer therapy. Nature Rev 6: 227-239, 2006. (Pubitemid 43292566)
35. Overall CM: Dilating the degradome: matrix metalloproteinase 2 (MMP-2) cuts to the heart of the matter. Biochem J 383(Pt 3): e5-7, 2004.
36. Overall CM and Kleifeld O: Towards third-generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer 4: 941-946, 2006.
37. Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC, Hawkins RE, McCulloch P, Maughan T, Brown PD, Baillet M and Fielding JW: Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 86: 1864-1870, 2002.
38. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M and Buckels JA: A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first-line therapy in patients with advanced pancreatic cancer. Br J Cancer 87: 161-167, 2002.
39. King J, Zhao J, Clingan P and Morris D: Randomised double-blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects. Anticancer Res 23: 639-645, 2003.
40. Dent P, Yacoub A, Contessa J, Caron R, Amorino G, Valerie K, Hagan MP, Grant S and Schmidt-Ullrich R: Stress and radiation-induced activation of multiple intracellular signalling pathways. Radiat Res 159: 283-300, 2003. (Pubitemid 36314943)
41. Schmidt-Ullrich RK, Contessa JN, Lammering G, Amorino G and Lin PS: ERBB receptor tyrosine kinases and cellular radiation responses. Oncogene 22: 5855-5865, 2003. (Pubitemid 37176706)
42. Suwinski R, Jaworska M, Nikiel B, Grzegorz W, Bankowska-Wozniak M, Wojciech M, Krzysztof S and Dariusz L: Predicting the effect of accelerated fractionation in postoperative radiotherapy for head and neck cancer based on molecular marker profiles: data from a randomized clinical trial. Int J Radiat Oncol Biol Phys 77(2): 438-446, 2010.